These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 29193928

  • 1. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
    Laboy-Ortiz IE, Velez-Maymí S, Hernán Martínez J, Trinidad R, Mangual M, Sanchez A, Gutierrez M, Mansilla P, Rivera C, Palermo C, de Lourdes Miranda M, Brau R.
    Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
    [Abstract] [Full Text] [Related]

  • 2. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
    Laboy-Ortiz IE, Velez-Maymí S, Hernán Martínez J, Trinidad R, Mangual M, Sanchez A, Gutierrez M, Mansilla P, Rivera C, Palermo C, Lourdes Miranda M, Brau R.
    Bol Asoc Med P R; 2016; 108(10066):29-34. PubMed ID: 29193914
    [Abstract] [Full Text] [Related]

  • 3. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 4. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P, Jaskuła M, Waśko R, Wołuń M, Sowiński J.
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [Abstract] [Full Text] [Related]

  • 5. Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
    de Castro LF, Magalhães Gonzaga MF, Naves LA, Luiz Mendonça J, Oton de Lima B, Casulari LA.
    Horm Res Paediatr; 2018 May; 89(1):63-70. PubMed ID: 28954263
    [Abstract] [Full Text] [Related]

  • 6. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S.
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [Abstract] [Full Text] [Related]

  • 7. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
    Kawabata Y, Ueno Y, Horikawa F, Miyake H, Miki N, Ono M.
    Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
    [Abstract] [Full Text] [Related]

  • 8. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK, Vance ML, Boulos PT, Laws ER.
    Pituitary; 2005 Jan; 8(1):53-60. PubMed ID: 16411069
    [Abstract] [Full Text] [Related]

  • 9. The cabergoline-resistant prolactinoma patient: new challenges.
    Molitch ME.
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4643-5. PubMed ID: 19056842
    [No Abstract] [Full Text] [Related]

  • 10. Non-surgical management of cystic prolactinomas.
    Bahuleyan B, Menon G, Nair S, Rao BR, Easwer HV, Krishna K.
    J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
    [Abstract] [Full Text] [Related]

  • 11. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Howell DL, Wasilewski K, Mazewski CM, Hudgins RJ, Meacham LR.
    J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
    [Abstract] [Full Text] [Related]

  • 12. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
    Delgrange E, Maiter D, Donckier J.
    Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
    [Abstract] [Full Text] [Related]

  • 13. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
    Oguz A, Tuzun D, Sahin M, Gul K.
    Niger J Clin Pract; 2016 Apr; 19(5):685-7. PubMed ID: 27538562
    [Abstract] [Full Text] [Related]

  • 14. Pituitary apoplexy associated with cabergoline therapy.
    Chng E, Dalan R.
    J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
    [Abstract] [Full Text] [Related]

  • 15. Women with prolactinomas presented at the postmenopausal period.
    Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A.
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [Abstract] [Full Text] [Related]

  • 16. Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.
    Tng EL, Teo AE, Aung AT.
    J Med Case Rep; 2023 Mar 17; 17(1):96. PubMed ID: 36927797
    [Abstract] [Full Text] [Related]

  • 17. Pharmacologic resistance in prolactinoma patients.
    Molitch ME.
    Pituitary; 2005 Mar 17; 8(1):43-52. PubMed ID: 16411068
    [Abstract] [Full Text] [Related]

  • 18. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Mar 17; 82(3):876-83. PubMed ID: 9062500
    [Abstract] [Full Text] [Related]

  • 19. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
    Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF.
    Clin Endocrinol (Oxf); 1997 Apr 17; 46(4):409-13. PubMed ID: 9196602
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.